Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07968101000 Ext: 1 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
Revenue from operations was at Rs 1,255.02 crore for the quarter ended 31 March 2022 as against Rs 1,095.54 crore during the same period in the previous year, registering a growth of 14.56%.
The drug maker's profit before tax surged 44.49% to Rs 292.30 crore in Q4 FY22 from Rs 201.88 crore in Q4 FY21.
On full year basis, the company reported a 15.64% increase in net profit to Rs 798.70 crore on a 14.14% declined in net sales to Rs 4,919.27 crore in FY22 over FY21.
Meanwhile, the board of directors of the company has recommended payment of final dividend of Rs 145 and a special dividend of Rs 130 per equity share, for the financial year ended 31 March 2022.
Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.
Powered by Capital Market - Live News